开发和验证用于预测帕金森病患者营养不良风险的诺姆图:一项回顾性队列研究
Qiaomin Tang1, Weiya Ma1, Yuanyuan Sun1
1Department of Nursing, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
概括
这项研究开发了一种名谱,用于预测帕金森病患者的营养不良风险. 该模型准确地识别了有风险的个体,有助于早期干预以获得更好的健康结果.
科学领域:
- 神经学 神经学
- 营养科学 营养科学
- 医疗信息学 医疗信息学
背景情况:
- 帕金森病 (PD) 是一种神经退行性疾病,通常与营养不良有关.
- 早期识别营养不良风险对于管理PD患者健康至关重要.
- 现有的营养不良评估方法可能无法适应PD的特定需求.
研究的目的:
- 开发和验证帕金森病患者营养不良风险的预测名录.
- 确定与PD中营养不良相关的关键临床和生理因素.
- 为临床医生提供一个工具,以有效地评估营养不良风险.
主要方法:
- 追溯队列研究涉及215名帕金森病患者.
- 使用最小绝对收缩和选择运算符 (LASSO) 和后勤回归来选择预测因素.
- 使用启动重抽样构建并内部验证了一个nomogram.
主要成果:
- 在研究队列中,营养不良的发病率为35.6%.
- 确定了七个重要的预测因素:低BMI,高级H-Y阶段,降低UPRDS-III改善率,低红细胞计数,低总胆固醇,高BUN和消化不良.
- 诺米图表表现出强大的预测性能,AUC为0.814.
结论:
- 一个经过验证的名图可以有效地预测帕金森病患者的营养不良风险.
- 已识别的预测因素为PD中营养不良的多因素性质提供了洞察力.
- 这种工具可以支持临床决策,以支持PD管理中的营养支持.
相关概念视频
Dosage Regimen Designs: Nomograms and Tabulations
181
Nomograms and tabulations are vital tools used by clinicians to design accurate and individualized dosage regimens. These instruments provide a straightforward method for adjusting dosages based on individual patient characteristics, including age, weight, and physiological condition. The foundation of a drug's nomogram is population pharmacokinetic data collected and analyzed using specific models. This data simplifies complex equations, presenting them diagrammatically or tabularly for easy...
181
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
190
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
190
Parkinson's Disease: Overview
1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K


